A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

NCT07700238 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG: Romiplostim
DRUG: Predniso(lo)ne

Sponsor

Amgen